Status:
UNKNOWN
RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection
Lead Sponsor:
A.O. Ospedale Papa Giovanni XXIII
Collaborating Sponsors:
San Raffaele University Hospital, Italy
Conditions:
HIV Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study evaluates efficacy and safety of rilpivirine as substitutive agent for the nucleosidic backbone of HAART in virologic suppressed patients when combined with cobicistat-boosted darunavir.
Detailed Description
HAART is generally based on the combination of three active drugs. Two of them, usually defined the backbone, belong to the nucleosidic analogues class (NRTI). In the last years, drugs of this class h...
Eligibility Criteria
Inclusion
- Written signed and dated informed consent to participate in the study must be given by the subject, in accordance with the International Conference of Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E627 and applicable regulations, before completing any procedure related to the study.
- HIV-1 documented infection
- Male and female subjects \> 18 years of age.
- Males, or non-pregnant, non-lactating females of childbearing potential, as demonstrated by a negative pregnancy test, who agree to comply with any applicable contraceptive requirements of the protocol. Women of child-bearing potential with a negative pregnancy test at Screening and Day 1 should agree to use one of the following methods: Complete abstinence from penile-vaginal intercourse from 2 weeks prior to administration of IMP, throughout the study, and for at least 2 weeks after; Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide) IUD and male condom Male partner sterilization confirmed and male condom Approved hormonal contraception and male condom Any other method with published data showing that the expected failure rate is \<1% per year and use male condo Any contraception method must be used for at least 2 weeks after discontinuation of IMP.
- Being on a stable therapy for at least 6 months.
- SBR must be based on any 2NRTI plus a third NNRTI, PI or INI agent. Any possible registered drug is allowed among NRTI (e.g. tenofovir, lamivudine, emtricitabine and abacavir), PI (e.g. lopinavir, atazanavir, darunavir), NNRTI (efavirenz, nevirapine, rilpivirine) or INI (raltegravir, elvitegravir, dolutegravir).
- Having a fully suppressed HIV replication as documented by 2 prior HIV-RNA tests (at least two months apart) below the detection limit (50 copies/ml).
- Subjects and investigator must agree that participation in this study is in the best interest of the subject.
Exclusion
- Patients co-infected with HBV
- Pregnancy or breast feeding.
- Positive anamnesis for allergy to NNRTI
- A positive historical genotypic test showing resistance-inducing mutation either toward NNRTIs or PIs
- History or other evidence of severe illness (malignancy or OI) requiring active treatment and/or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
- Anticipated need for Hepatitis C virus (HCV) therapy during the study period
- Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses
- All conditions and medicinal products listed in contraindications of DRV/c and rilpivirine
- Subjects with current or prior (previous year) history of alcohol or other substance abuse.
- Patients who have previously been screened for or enrolled into this study and subsequently withdrawn.
- Patients having been given investigational drugs within 12 weeks prior to screening.
- Inability or unwillingness to provide informed consent.
- Life expectancy \< 18 months
Key Trial Info
Start Date :
February 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2019
Estimated Enrollment :
1609 Patients enrolled
Trial Details
Trial ID
NCT04064632
Start Date
February 1 2017
End Date
November 30 2019
Last Update
August 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Antiviral Therapy Unit, Ospedali Riuniti
Bergamo, Italy, 24128